Document is current
Any future updates will be listed below
-
Authors
Duff, Eugene P. https://orcid.org/0000-0001-8795-5472
Zetterberg, Henrik
Heslegrave, Amanda
Dehghan, Abbas https://orcid.org/0000-0001-6403-016X
Elliott, Paul https://orcid.org/0000-0002-7511-5684
Allen, Naomi https://orcid.org/0000-0003-1938-5038
Runz, Heiko https://orcid.org/0000-0002-2133-7345
Laban, Rhiannon https://orcid.org/0000-0002-5926-8357
Veleva, Elena
Whelan, Christopher D. https://orcid.org/0000-0003-0308-5583
Sun, Benjamin B. https://orcid.org/0000-0001-6347-2281
Matthews, Paul M. https://orcid.org/0000-0002-1619-8328
- License Information
-
More Information
Article History
Received: 31 December 2023
Accepted: 22 November 2024
First Online: 30 January 2025
Competing interests
: The authors declare the following competing interests. P.M.M. is a consultant for Biogen, Sudo Therapeutics, Nimbus, Astex, GSK and Sangamo. He received research funding for aspects of this work from Biogen and the UK DRI. P.M.M. has also received research funding unrelated to this work from Biogen and Bristol Meyers Squibb. H.R. and B.B.S. were full-time employees at Biogen during the data generation for this study. B.B.S. is an employee of Bristol Myers Squibb. H.R. is an employee at insitro Inc. H.Z. has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics and Wave; has given lectures in symposia sponsored by Alzecure, Biogen, Cellectricon, Fujirebio, Lilly and Roche; and is a cofounder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. C.D.W. is an employee of Johnson & Johnson Innovative Medicine. No organizations listed here made any contributions to the conceptualization or preparation of this study beyond the disclosed individual contributions of authors who were employees. They are listed only for the potential perception of competing interests associated with drug or biomarker development. The other authors declare no competing interests.
